Table 4.
The efficacy of subsequent endocrine therapy for advanced breast cancer who have failed to respond to non–steroidal aromatase inhibitor
| Author; Journal, year (Trial name) | Line | Design | n | ORR (%) | CBR (%) |
|---|---|---|---|---|---|
| Lϕnning; J Clin Oncol, 2000
[9] |
2nd ~ 4th |
nsAI → EXE |
105 |
4.8 |
20.0 |
| Iaffaioli; Br J Cancer, 2005
[10] |
2nd ~ 3rd |
ANA → EXE |
50 |
8.0 |
44.0 |
| Steele; Breast, 2005
[4] |
2nd~ > 4th |
nsAI → EXE |
114 |
5.0 |
46.0 |
| Thürlimann; Eur J Cancer, 2003
[13] |
2nd |
ANA → TAM |
119 |
10.1 |
48.7 |
| Chia; J Clin Oncol, 2008 (EFECT)
[12] |
2nd~ > 4th |
nsAI → FUL loading dose |
270 |
7.4 |
32.2 |
| nsAI → EXE |
270 |
6.7 |
31.5 |
||
| Yamamoto; Breast Cancer, 2010 (Hi-FAIR)
[8] |
2nd~ > 4th |
AIs → TOR120 |
80 |
15.0 |
45.0 |
| Di Leo; J Clin Oncol, 2010
[14] |
2nd |
AI or SERM → FUL500 |
362 |
9.1 |
45.6 |
| AI or SERM → FUL250 |
374 |
10.2 |
39.6 |
||
| Bachelot T: J Clin Oncol. 2012 (TAMRAD)
[17] |
2nd~ > 4th |
nsAI → TAM |
57 |
13.0 |
42.1 |
| nsAI → TAM + RAD001 |
54 |
14.0 |
61.1 |
||
| Baselga; N Engl J Med, 2012 (Bolero2) [16] | 2nd ~ 4th | nsAI → EXE |
239 |
0.4 |
18.0 |
| nsAI → EXE + RAD001 | 484 | 9.5 | 33.4 |
nsAI: non-steroidal aromatase inhibitor, EXE: exemestane, ANA: anastrozle, TAM: tamoxifen, FUL: fulvestrant, SERM: selective estrogen receptor modulator.